Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus or Fluzoparib with Fulvestrant and Abemaciclib in HR+/HER2- Breast Cancer
NCT06561022Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, fluzoparib in breast cancer, sponsored by Fudan University. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
everolimusfluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06561022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561022.